Cantor Fitzgerald Initiates Coverage On Avidity Biosciences with Overweight Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has initiated coverage on Avidity Biosciences (NASDAQ:RNA) with an Overweight rating and set a price target of $60.
March 14, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avidity Biosciences received an Overweight rating from Cantor Fitzgerald with a price target of $60.
The initiation of coverage by a reputable analyst with an Overweight rating and a high price target typically signals confidence in the company's future performance, potentially leading to increased investor interest and a positive short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100